Show summary Hide summary
Henry Schein delivered a earnings beat that surprised investors last week. The dental and medical distributor reported $1.32 non-GAAP EPS for Q1 2026, crushing analyst expectations. Revenue expansion of 6.3% year-over-year signals the global leader is gaining market momentum.
🔥 Quick Facts
- Q1 EPS Performance: $1.32 non-GAAP, beating consensus est. of $1.20 by $0.12 (10% surprise)
- Revenue Growth: $3.37 billion total sales with 6.3% year-over-year increase
- Global Dental Sales: $1.77 billion, up 9% from Q1 2025, highest growth segment
- Full-Year Guidance: Reaffirmed $5.23 to $5.37 annual EPS, 3% to 5% sales growth forecast
Beating Expectations on Dental Strength
Henry Schein reported its earnings last Monday, May 5th, significantly outperforming analyst projections. The company generated $1.32 per share in non-GAAP earnings, compared to the consensus estimate of just $1.20, delivering a 10% surprise that energized markets.
Revenue came in at $3.37 billion, representing 6.3% growth versus the prior year. This beat analyst expectations of $3.34 billion by 0.8%, demonstrating strong execution across both its dental and medical distribution operations. The North America’s largest dental supply company is successfully expanding market share despite a competitive landscape.
SLS stock surges after earnings beat, leukemia drug trial nears key data
QS stock slides as QuantumScape unveils Eagle Line battery partnerships
Global Dental Distribution Leads The Charge
The company’s Global Dental Distribution segment emerged as the primary growth driver for the quarter. Dental distribution revenue totaled $1.77 billion, representing an impressive 9% year-over-year increase compared to Q1 2025.
Breaking down the segment further, dental merchandise sales climbed by 9.0%, while equipment sales surged 8.6%. Internal sales growth in dental merchandise reached 3.0%, indicating organic expansion beyond acquisitions. These results highlight market share gains and strong demand in the dental practice market as practitioners invest in supplies and equipment.
Financial Metrics That Matter
| Metric | Q1 2026 Result |
| Revenue | $3.37 billion (6.3% growth) |
| Non-GAAP EPS | $1.32 vs. $1.20 consensus |
| Adjusted EBITDA | $289 million |
| FX Impact | +$0.03 per share benefit |
| Full-Year EPS Guidance | $5.23 to $5.37 (reaffirmed) |
“Strong first quarter results reflect continuing momentum from the second half of last year as we grow market share and expand margins.”
— Henry Schein Management, Q1 2026 Earnings Report
Strategic Leadership Transition and Forward Momentum
Frederick M. Lowery assumed the role of Chief Executive Officer in March 2026, replacing legend Stanley Bergman after his 35-year tenure. Bergman, who spent 45 years at Henry Schein, transitioned to Chairman Emeritus in recognition of his transformational leadership tenure.
The company maintained its 2026 full-year guidance at $5.23 to $5.37 per share in non-GAAP diluted earnings. Management expects 3% to 5% sales growth for the full year. This stability signals confidence that the company’s growth trajectory remains intact under new leadership, with strong operational momentum and margin expansion initiatives underway.
What This Means for Investors and the Dental Industry
Henry Schein’s Q1 beat underscores resilience in the dental supplies market as practitioners continue investing in operations. The 9% dental segment growth suggests dental practice activity remains healthy, and market share expansion indicates Henry Schein is outpacing competitors. With 6.3% revenue growth and strong guidance reaffirmation, what signals are institutional investors reading from this earnings report?
